The chronic myeloid leukemia treatment Scemblix (asciminib, Novartis) was passed the Drug Reimbursement Evaluation Committee review for costing the same as another 3rd generation CML treatment, Iclusig (ponatinib, Otsuka),

The company agreed to set its price at 100% or below the weighted average price of its therapeutic alternative to waive the drug pricing negotiation process and succeeded in being listed within one year since it applied for reimbursement on July 27 last year.

According to industry sources on the 20th, the DREC’s evaluation results on Scemblix were recently disclosed by the Health Insurance Review and Assessment Service showed that the cost of Scemblix, which was the